Stavros Vlatakis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Stavros Vlatakis has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Maya Thanou
School of Cancer and Pharmaceutical Sciences, King’s College London
3 shared publications - Weiqi Zhang
School of Biomedical Engineering and Imaging Sciences
3 shared publications - Hilde Metzger
James Watt School of Engineering, University of Glasgow, Glasgow, UK
2 shared publications Aaran Vijayakumaran
School of Cancer & Pharmaceutical Sciences, King's College London, UK
1 shared publication- Alexandru Corneliu Moldovan
James Watt School of Engineering, University of Glasgow, Glasgow G12 8QQ, UK
1 shared publication - Amelia Claxton
Innovation Hub, Comprehensive Cancer Centre, King’s College London, Great Maze Pond, London SE1 9RT, UK
1 shared publication
Latest Publications
- Open Access
- 28 December 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (1) , 51
Effect of Phase-Change Nanodroplets and Ultrasound on Blood–Brain Barrier Permeability In Vitro
Phase-change nanodroplets (PCND;NDs) are emulsions with a perfluorocarbon (PFC) core that undergo acoustic vaporisation as a response to ultrasound (US). Nanodroplets change to microbubbles and cavitate while under the effect of US. This cavitation can apply forces on cell connections in biological barrier membranes, such as the blood–brain barrier (BBB), and trigger a transient and reversible increased permeability to molecules and matter. This study aims to present the preparation of lipid-based NDs and investigate their effects on the brain endothelial cell barrier in vitro. The NDs were prepared using the thin-film hydration method, followed by the PFC addition. They were characterised for size, cavitation (using a high-speed camera), and PFC encapsulation (using FTIR). The bEnd.3 (mouse brain endothelial) cells were seeded onto transwell inserts. Fluorescein with NDs and/or microbubbles were applied on the bEND3 cells and the effect of US on fluorescein permeability was measured. The Live/Dead assay was used to assess the BBB integrity after the treatments. Size and PFC content analysis indicated that the NDs were stable while stored. High-speed camera imaging confirmed that the NDs cavitate after US exposure of 0.12 MPa. The BBB cell model experiments revealed a 4-fold increase in cell membrane permeation after the combined application of US and NDs. The Live/Dead assay results indicated damage to the BBB membrane integrity, but this damage was less when compared to the one caused by microbubbles. This in vitro study shows that nanodroplets have the potential to cause BBB opening in a similar manner to microbubbles. Both cavitation agents caused damage on the endothelial cells. It appears that NDs cause less cell damage compared to microbubbles.
- 28 December 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (1) , 51
Open AccessEffect of Phase-Change Nanodroplets and Ultrasound on Blood–Brain Barrier Permeability In Vitro
Phase-change nanodroplets (PCND;NDs) are emulsions with a perfluorocarbon (PFC) core that undergo acoustic vaporisation as a response to ultrasound (US). Nanodroplets change to microbubbles and cavitate while under the effect of US. This cavitation can apply forces on cell connections in biological barrier membranes, such as the blood–brain barrier (BBB), and trigger a transient and reversible increased permeability to molecules and matter. This study aims to present the preparation of lipid-based NDs and investigate their effects on the brain endothelial cell barrier in vitro. The NDs were prepared using the thin-film hydration method, followed by the PFC addition. They were characterised for size, cavitation (using a high-speed camera), and PFC encapsulation (using FTIR). The bEnd.3 (mouse brain endothelial) cells were seeded onto transwell inserts. Fluorescein with NDs and/or microbubbles were applied on the bEND3 cells and the effect of US on fluorescein permeability was measured. The Live/Dead assay was used to assess the BBB integrity after the treatments. Size and PFC content analysis indicated that the NDs were stable while stored. High-speed camera imaging confirmed that the NDs cavitate after US exposure of 0.12 MPa. The BBB cell model experiments revealed a 4-fold increase in cell membrane permeation after the combined application of US and NDs. The Live/Dead assay results indicated damage to the BBB membrane integrity, but this damage was less when compared to the one caused by microbubbles. This in vitro study shows that nanodroplets have the potential to cause BBB opening in a similar manner to microbubbles. Both cavitation agents caused damage on the endothelial cells. It appears that NDs cause less cell damage compared to microbubbles.
- Open Access
- 17 May 2023
- Published by Elsevier in Ultrasonics Sonochemistry
- Vol. 97, 106445
Characterising the chemical and physical properties of phase-change nanodroplets
- 17 May 2023
- Published by Elsevier in Ultrasonics Sonochemistry
- Vol. 97, 106445
Open AccessCharacterising the chemical and physical properties of phase-change nanodroplets
- Open Access
- 9 May 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1444
Real-Time Monitoring Platform for Ocular Drug Delivery
Real-time measurement is important in modern dissolution testing to aid in parallel drug characterisation and quality control (QC). The development of a real-time monitoring platform (microfluidic system, a novel eye movement platform with temperature sensors and accelerometers and a concentration probe setup) in conjunction with an in vitro model of the human eye (PK-Eye™) is reported. The importance of surface membrane permeability when modelling the PK-Eye™ was determined with a “pursing model” (a simplified setup of the hyaloid membrane). Parallel microfluidic control of PK-Eye™ models from a single source of pressure was performed with a ratio of 1:6 (pressure source:models) demonstrating scalability and reproducibility of pressure-flow data. Pore size and exposed surface area helped obtain a physiological range of intraocular pressure (IOP) within the models, demonstrating the need to reproduce in vitro dimensions as closely as possible to the real eye. Variation of aqueous humour flow rate throughout the day was demonstrated with a developed circadian rhythm program. Capabilities of different eye movements were programmed and achieved with an in-house eye movement platform. A concentration probe recorded the real-time concentration monitoring of injected albumin-conjugated Alexa Fluor 488 (Alexa albumin), which displayed constant release profiles. These results demonstrate the possibility of real-time monitoring of a pharmaceutical model for preclinical testing of ocular formulations.
- 9 May 2023
- Published by MDPI AG in Pharmaceutics
- Vol. 15 (5) , 1444
Open AccessReal-Time Monitoring Platform for Ocular Drug Delivery
Real-time measurement is important in modern dissolution testing to aid in parallel drug characterisation and quality control (QC). The development of a real-time monitoring platform (microfluidic system, a novel eye movement platform with temperature sensors and accelerometers and a concentration probe setup) in conjunction with an in vitro model of the human eye (PK-Eye™) is reported. The importance of surface membrane permeability when modelling the PK-Eye™ was determined with a “pursing model” (a simplified setup of the hyaloid membrane). Parallel microfluidic control of PK-Eye™ models from a single source of pressure was performed with a ratio of 1:6 (pressure source:models) demonstrating scalability and reproducibility of pressure-flow data. Pore size and exposed surface area helped obtain a physiological range of intraocular pressure (IOP) within the models, demonstrating the need to reproduce in vitro dimensions as closely as possible to the real eye. Variation of aqueous humour flow rate throughout the day was demonstrated with a developed circadian rhythm program. Capabilities of different eye movements were programmed and achieved with an in-house eye movement platform. A concentration probe recorded the real-time concentration monitoring of injected albumin-conjugated Alexa Fluor 488 (Alexa albumin), which displayed constant release profiles. These results demonstrate the possibility of real-time monitoring of a pharmaceutical model for preclinical testing of ocular formulations.
- 15 February 2022
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 14 (8) , 2943-2965
Phase-shift nanodroplets as an emerging sonoresponsive nanomaterial for imaging and drug delivery applications
The scheme of loading drugs/decorations in nanodroplets and US/laser irradiated drug release (figure created with BioRender.com).
- 15 February 2022
- Published by Royal Society of Chemistry (RSC) in Nanoscale
- Vol. 14 (8) , 2943-2965
Phase-shift nanodroplets as an emerging sonoresponsive nanomaterial for imaging and drug delivery applications
The scheme of loading drugs/decorations in nanodroplets and US/laser irradiated drug release (figure created with BioRender.com).